Daewoong's SGLT-2 Inhibitor Set For First Filing After Phase III

First Korean Contender In Class

 
• By Jung Won Shin
  
diabetes
Daewoong Speeds Up Novel Drug Development • Source: Alamy

More from South Korea

More from Focus On Asia